Touro Scholar

COVID-19 Newsletter

NYMC Publications

8-2-2022

COVID-19 Newsletter (Vol. 130)

Center for Disaster Medicine, New York Medical College

Follow this and additional works at: https://touroscholar.touro.edu/nymc_covid19_newsletter

Part of the Infectious Disease Commons, Influenza Humans Commons, and the Virus Diseases Commons

From: NYMC_COVID19Newsletter on behalf of Disaster Medicine
To: NYMC_COVID19NEWSLETTER@LISTSERV.TOURO.EDU
Subject: Center for Disaster Medicine Information Brief
Date: Tuesday, August 2, 2022 4:17:28 PM

Attachments: image003.png





Tuesday, August 2, 2022

As the COVID-19 pandemic continues to evolve, we are seeing other emerging public health threats/emergencies and we continue to address ongoing/emerging disaster issues, the Center for Disaster Medicine has been and will continue to be a source of reliable information, education and models for mitigation, preparedness, response, and recovery. As such we are expanding this informational document to address the broader areas addressed by the center while retaining critical COVID19 information. You will notice we have updated the name to CDM Info Brief. As the pace of new information and changes occur, we will evaluate the current once per week to determine if this information should be provided on a more frequent basis.

David Markenson, M.D., M.B.A.


Director

Center for Disaster Medicine

COVID-19 Statistics

| | Total Cases | Total Deaths | Total Vaccine Doses Admin. |
|---------------|-------------|--------------|-------------------------------|
| Worldwide | 578,284,562 | 6,402,795 | 11,973,568,249 |
| United States | 91,472,958 | 1,030,499 | 599,865,455 |
| New Jersey | 2,599,211 | 34,270 | 17,925,211 |
| New York | 5,833,909 | 70,321 | 40,706,749 |
| Connecticut | 854,934 | 11,102 | 7,958,343 |

United States COVID-19 Case Map / GIS



Center for Disaster Medicine Updates

- Coordinating and overseeing COVID-19 screenings at NYMC campus.
- Continue to partner with local organizations such as Westchester Department of Emergency Services and Westchester Medical Center to ensure ongoing collaboration with all public safety agencies.
- Coordinating volunteers to support local public health response to COVID-19.
- Conducting research and analysis of current events and COVID-19 response to identify strengths and areas for improvement in other regions.
- Updating and developing new programs to provide enhanced education on public health emergencies including pandemics.
- Exploring course development opportunities in infection prevention and control for frontline responders in the hospital and in the field
- Serving as a source of information for COVID-19 related concerns or questions regarding public health, emergency medical service (EMS), public safety and healthcare response.
- Local networking and pandemic response analysis for New York's tri-state area, using first-person experiences to highlight current trends
- On July 21, 2022, CDM staff provided STOP THE BLEED workshop to staff and students of the NYMC community. This life-saving training is ongoing on a monthly basis so that everyone has an opportunity to raise their level of awareness and knowledge.

The White House

The official website of the White House will deliver updated information as the country grapples with converging crises. This will include actions to control current public health threats, provide economic relief, tackle climate change, and advance racial equity and civil rights, as well as immediate actions to reform our immigration system and restore America's standing in the world. This website will provide all information in one central location.

 President Biden named FEMA's Robert Fenton as the White House National Monkeypox Response Coordinator and Dr. Demetre Daskalakis as the White House National Monkeypox Response Deputy Coordinator. Fenton and Daskalakis will lead the Administration's strategy and operations to combat the current monkeypox outbreak, including equitably increasing the availability of tests, vaccinations and treatments. Robert Fenton currently serves as Regional Administrator for FEMA Region 9 in the American West, with nearly 50 million people in his area of responsibility. One of the nation's most experienced and effective emergency management leaders, Robert Fenton has twice served as Acting Administrator of FEMA and led multiple challenging prevention, response and recovery operations throughout his long and distinguished career, including for natural disasters, disease outbreaks, and complex humanitarian operations. Demetre Daskalakis, a leading public health expert, is currently Director of the CDC Division of HIV Prevention. Widely known as a national expert on health issues affecting the LGBGQIA+ communities, his clinical practice has focused on providing care for the underserved LGBTQIA+ communities. He previously oversaw management of infectious diseases for the New York City Department of Health and Mental Hygiene, one of the largest departments in the nation including in serving as incident commander for the City's COVID-19 response. Fenton and Daskalakis combined have more than four decades of experience in Federal emergency response and public health leadership, including overseeing the operations and implementation of key components of the Biden Administration's response to the COVID-19 pandemic, and leading local and Federal public health emergency efforts such as infectious disease control and HIV prevention. Both played critical roles in making COVID vaccines more accessible for underserved communities and closing the equity gap in adult vaccination rates, through the implementation and execution of FEMA mass vaccination sites in some of the country's most underserved communities, and working with trusted members of local communities to build vaccine confidence. For more on this release, plesase visit https://www.whitehouse.gov/briefing-room/statementsreleases/2022/08/02/president-biden-announces-team-to-lead-monkeypox-response/

https://www.whitehouse.gov

COVID-19 Website

On March 30, 2022, Biden Administration Launched COVID.gov, a New One-Stop Shop Website for Vaccines, Tests, Treatments, Masks, and the Latest COVID-19 Information- a new website was launched in an effort to consolidate information for consumers. https://www.whitehouse.gov/briefing-room/statements-releases/2022/03/30/fact-sheet-biden-administration-launches-covid-gov-a-new-one-stop-shop-website-for-vaccines-tests-treatments-masks-and-the-latest-covid-19-information/

Health and Human Services (HHS)

• The U.S. Department of Health and Human Services (HHS), in collaboration with the U.S. Department of Defense (DOD), announced an agreement to purchase 66 million doses of Moderna's bivalent COVID-19 vaccine booster candidate for potential use in the fall and winter. This contract announcement follows a recommendation by the FDA last month that vaccine manufacturers update their existing COVID-19 vaccines to create a bivalent booster that can target BA.4 and BA.5 Omicron subvariants. This purchase is in addition to the 105 million bivalent COVID-19 vaccine booster doses the U.S. government purchased recently from Pfizer for potential use later this year, pending FDA authorization and a recommendation by CDC. Pending those FDA and CDC actions, HHS would receive the first deliveries of the Moderna and Pfizer vaccine booster doses in early fall. "We must stay vigilant in our fight against COVID-19 and continue to expand Americans' access to the best vaccines and treatments," said HHS Secretary Xavier Becerra. "As we look to the fall and winter, we're doing just that—ensuring Americans have the tools they need to stay safe and help keep our nation moving forward." "We look forward to receiving these new variantspecific vaccines and working with state and local healthcare partners to make the vaccines available for free in communities around the country this fall," said HHS Assistant Secretary Dawn O'Connell who leads the Administration for Strategic Preparedness and Response (ASPR). Existing COVID-19 vaccines remain the single most important tool in preventing serious illness, hospitalization, and death, and given the current threat that BA.5 Omicron subvariant poses, it is essential that Americans stay up to date with their COVID-19 vaccinations. At the same time, the virus is dynamic, and the Administration continues to act aggressively to ensure that Americans have access to the latest, most protective vaccines as quickly as they become available. https://www.hhs.gov/about/news/2022/07/29/bidenharris-administration-secures-66-million-doses-modernas-variant-specific-covid-19-vaccinebooster-for-potential-use-in-fall-winter-2022.html

For the latest COVID-19 information from HHS https://www.hhs.gov/about/news/coronavirus/index.html

National Institutes of Health (NIH)

View the latest COVID-19 information from NIH. https://www.nih.gov/coronavirus

Centers for Disease Control and Prevention (CDC)

CDC provides updated information about the variants in the United States- The emerging variants CDC is closely monitoring have mutations in the virus genome that alter the characteristics and cause the virus to act differently in ways that are

significant to public health (e.g., causes more severe disease, spreads more easily between humans, requires different treatments, changes the effectiveness of current vaccines). It's important to understand that genetic mutations are expected, and some variants can spread and become predominant while others subside. https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.htm

CDC provides daily data tracker which has maps and charts tracking cases, deaths, and trends of COVID-19 in the United States- updated daily by 8 p.m. ET. https://covid.cdc.gov/covid-data-tracker/#datatracker-home

For the latest CDC information https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/index.html

United States Food and Drug Administration (FDA)

- The FDA updated the FAQs on Testing for SARS-CoV-2 to note that no tests remain on the commercial manufacturer serology test notification list described in the FDA's Policy for Coronavirus Disease-2019 Tests. All tests previously on the commercial manufacturer serology test notification list have either been issued an Emergency Use Authorization or should no longer be distributed, marketed, or offered
- The U.S. Food and Drug Administration is providing an update on its multipronged response to monkeypox in the United States, including its efforts in the areas of diagnostics, vaccines and therapeutics. The agency has also established a dedicated website to provide important information about the FDA's ongoing regulatory activities related to monkeypox along with frequently asked questions. The FDA will provide updates as developments occur and will continue to work with federal public health partners and industry to ensure timely access to all available medical countermeasures. "The FDA has been closely tracking reports of monkeypox transmissions in the United States with our federal public health partners and coordinating preparedness efforts accordingly," said FDA Commissioner Robert M. Califf, M.D. "We understand that while we are still living with COVID-19, an emerging disease may leave that while we are still living with COVID-19, an emerging disease may leave people feeling concerned and uncertain, but it's important to note that we already have medical products in place, specifically an FDA-approved vaccine for the prevention of monkeypox disease and an FDA-cleared diagnostic test. The FDA is using the full breadth of its authorities to make additional diagnostics and treatments available. We will continue to collaborate with our partners across all sectors to expand accessibility to countermeasures and bolster the tools in our arsenal as appropriate." The monkeypox virus is part of the same family of viruses as variola virus, the virus that causes smallpox (a virus that has been eradicated globally). Both monkeypox and smallpox fall into the category of "orthopoxviruses." Monkeypox is generally not fatal and typically resolves on its own without treatment. The current outbreak in the U.S. usually presents as a rash on the body, face or genital area. Although there is a very low risk of dying, there have been reported complications including severe pain, at times requiring hospital admission.
 - Diagnostics
 - Since the first case of monkeypox in the U.S. was detected, the FDA has been working with commercial laboratories and manufacturers to make monkeypox tests more readily available to consumers who need them. The Centers for Disease Control and Prevention (CDC) has an FDA-cleared non-variola orthopoxvirus test that can detect monkeypox by a swab from a monkeypox lesion (rash or growth). At this time, this is the only FDA-cleared test. The FDA is not aware of clinical data supporting the use of other sample types, such as blood or saliva, for monkeypox virus testing. In July 2022, the FDA issued a safety communication advising people to use swab samples taken directly from a lesion when testing for the monkeypox virus.
 - The FDA-cleared monkeypox test is being offered by the CDC and throughout many laboratories that include the CDC's public health Laboratory Response Network. In addition, federal public health authorities have worked with industry to make the test available through five large commercial laboratories. The agency is working closely with the CDC to increase production of its FDA-cleared test and the FDA has cleared the use of additional reagents and instruments to increase the throughput of the CDC
 - The FDA will continue to work with the diagnostic community to augment access to accurate testing to support the response.

Vaccines

- In 2019, the FDA approved the JYNNEOS Vaccine for the prevention of smallpox and monkeypox in adults 18 years of age and older determined to be at high risk of infection. JYNNEOS is the only vaccine approved for the prevention of monkeypox in the United States. Although clinical trials and data are limited because of the small number of cases until now, the immunological response to vaccine administration is consistent with effective prevention of the disease.
- Following the emerging public health crisis closely, the FDA was aware that there were close to 800,000 doses of this vaccine pending release this fall following approval of additional manufacturing capabilities at one of the plants where the vaccine is made. With this in mind, the agency worked with HHS partners and expedited the submission of the required

application for the company's manufacturing changes in order to make these doses available to those in need. After accelerating the timeline for an inspection of the plant from fall to earlier this month, the FDA has finished its evaluation of the required information to validate product quality and has determined that the vaccine meets its quality standards.

On July 26, the agency approved a supplement to the biologics license for the JYNNEOS Vaccine, to allow for additional manufacturing capabilities at the facility. Given the emerging public health need, the FDA previously facilitated the shipment of manufactured doses to the U.S. so that they would be ready to be distributed once the manufacturing changes were approved. With the supplement approval, those manufactured doses may now be further distributed and administered. Additional doses manufactured at this plant can help address the need for this vaccine moving forward.

Therapeutics

- There is no FDA-approved or authorized medicine for the treatment of monkeypox disease; however, TPOXX (tecovirimat), an antiviral medication, is being made available through the CDC under an FDA authority called Expanded Access or "compassionate use." The FDA continues to work with the CDC to streamline their Expanded Access Program for monkeypox to facilitate access.
- There are currently no human data demonstrating the efficacy of TPOXX for the treatment of monkeypox, or the safety and pharmacokinetic profile (which helps us understand what the human body does to a drug). Although expanded access program is available, conducting randomized, controlled trials to assess TPOXX's safety and efficacy in humans with monkeypox infections is essential.
- The FDA has more information on TPOXX's approval for smallpox under the "Animal Rule" regulations on its monkeypox webpage.
- · COVID-19 testing updates:
 - As of today, 438 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 301 molecular tests and sample collection devices, 85 antibody and other immune response tests, 51 antigen tests, and 1 diagnostic breath test. There are 78 molecular authorizations and 1 antibody authorization that can be used with home-collected samples. There is 1 EUA for a molecular prescription at-home test, 2 EUAs for antigen prescription at-home tests, 19 EUAs for antigen over-the-counter (OTC) at-home tests, and 3 for molecular OTC at-home tests.
 - The FDA has authorized 31 antigen tests and 8 molecular tests for serial screening programs. The FDA has also authorized 1062 revisions to EUA authorizations.

For the latest overall FDA information about COVID-19. https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19

Center for Medicare and Medicaid Services (CMS)

View the latest information from CMS

https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPRO/Current-Emergencies/Current-Emergencies-page

Vaccines

CDC created this section regarding COVID-19 vaccinations in the United States-CDC provides overall US COVID-19 Vaccine, deliveries and administration, maps, charts, and data updated daily by 8 PM. This section represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities. https://covid.cdc.gov/covid-data-tracker/#vaccinations

 The CDC has established a new website dedicated to the monkeypox virus and 2022 U.S. outbreak. For more information, please visit https://www.cdc.gov/poxvirus/monkeypox/index.html

The NYS DOH COVID-19 Vaccine Tracker Dashboard will update New Yorkers on the distribution of the vaccine including the number of doses received by the state, a breakdown of first or second doses, and the number of persons vaccinated with the first and second doses in each region.

https://covid19vaccine.health.ny.gov/covid-19-vaccine-tracker

CDC created this section regarding the Johnson & Johnson's Janssen vaccine to provide updated relevant information including side effects and safety data, clinical

trials demographic statistics, and information on how the vaccine works. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/janssen.html

CDC created this section regarding the Moderna vaccine to provide updated relevant information including side effects and safety data, clinical trials demographic statistics, and information on how the vaccine works.

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Moderna.html

CDC created this section regarding the Pfizer BioNTech vaccine to provide updated relevant information including side effects and safety data, clinical trials demographic statistics, and information on how the vaccine works. As of October 16, 2021, the fully FDA approved Pfizer vaccine will now be known as COMIRNATY for ages 16 and

https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html

HHS created this section to provide the latest information about COVID-19 vaccines. https://www.hhs.gov/coronavirus/covid-19-vaccines/index.html

For NYC DOHMH updated guidance regarding COVID-19 vaccine https://www1.nyc.gov/site/doh/covid/covid-19-vaccines.page

The Vaccine Finder is a one-stop site for New Yorkers to find their nearest COVID-19 vaccination location. The Vaccine Finder can also provide New Yorkers with information to schedule vaccination appointments. https://vaccinefinder.nyc.gov/

Educational Institution Information

- Higher Education
 - · The Pennsylvania State System of Higher Education recently merged six of its public universities into two multicampus institutions as part of an ongoing effort to maintain the system as a driver of economic development and social mobility in the state. State officials rewarded those efforts by approving PASSHE's largest budget increase ever. But amid this significant reorganization, a quieter, yet still noteworthy, change also occurred. PASSHE sold its Dixon University Center, the downtown Harrisburg building and grounds that formerly housed the Office of the Chancellor. The sale reduced operating expenses and generated an estimated annual savings of \$2 million, according to Kevin Hensil, a PASSHE spokesperson. The sale also provided the university system an opportunity to allow the office's 27 employees to work remotely on a permanent basis at a time when colleges and universities are bleeding employees and looking for ways to retain workers feeling battered by the pandemic and burned out from heavy workloads. By being more flexible with remote work policies, the system's leaders are also reacting to post-pandemic workplace pressures to innovate with the goal of optimizing employee productivity and job satisfaction.

https://www.insidehighered.com/news/2022/07/29/building-sale-remote-work-helped-pa-system-redesign

• K-12

- District leaders combined classes, bumped pay for substitute teachers, asked teachers to take on more duties, and had central staff lead classes during the 2021-22 school year as school systems continued to recover from COVID-19-related impacts, according to a study by the RAND Corp. The study found 90 percent of school districts changed operations in one or more of their schools last school year and that more than three-quarters of districts have added instructional and noninstructional staff compared to pre-pandemic levels. RAND surveyed a random sample of 291 district and charter network leaders between February 28, 2022, and April 10, 2022, for its fifth American School District Panel Survey. The study said that although it is not clear why districts choose certain operational changes over others, differences in access to federal COVID-19 relief funds likely played a role in the ability to increase pay and hiring to address understaffing. https://www.k12dive.com/news/districts-shuffle-operations-in-responseto-covid-19/628411/
- Despite a new COVID-19 variant that has led to another surge in cases, mask mandates are continuing to loosen in school districts getting ready to open for the new school year. A new wave of cases tied to omicron subvariant BA.5 is expected to go on for the beginning of the

2022-23 school year, Mara Aspinall, a professor of practice at Arizona State University's College of Health Solutions and COVID-19 testing advisor to the Rockefeller Foundation, told K-12 Dive last week. Overall, districts upholding mask mandates into the new school year appear to be in the minority. As of Monday, six of the top 500 districts — or 1.2 percent — are requiring masks, according to data tracking company Burbio. By comparison, 369 of 500 districts (73.8 percent) required masks in October of 2021, Burbio found. https://www.k12dive.com/news/school-mask-mandates-continue-to-loosen/628527/

Clinical Trials

To view the latest information on clinical trials regarding COVID-19 https://www.clinicaltrials.gov/ct2/results?
recrs=&cond=Covid19&term=&cntry=&state=&city=&dist=

American Red Cross

https://www.redcrossblood.org/donate-blood/dlp/plasma-donations-from-recovered-covid-19-patients.html

State Updates


New York

- Statement by Governor Hochul: "I am grateful to President Biden and other Administration officials for their help in securing an additional 110,000 monkeypox vaccine doses approximately 80,000 to New York City and 30,000 to the rest of New York State which will be delivered over the next four to six weeks and allow us to continue to respond to this troubling outbreak. This builds on the more than 60,000 monkeypox doses that New York City and New York State have received to date due to our ongoing coordination with the federal government. "With more than one-quarter of all cases in the U.S., New Yorkers, and especially our LGBTQ+ community, remain among the hardest-hit. We will continue to advocate to the federal government for our fair share of vaccines based on the disease burden impacting New York." "My team and I have been working around the clock to confront the monkeypox outbreak and keep New Yorkers safe, and we will continue our ongoing efforts to secure more vaccines, expand testing capacity, and educate the public on how to identify symptoms and protect themselves." https://www.governor.ny.gov/news/statement-governor-kathy-hochul-110000-additional-monkeypox-vaccine-doses-new-york-state-and
- Governor Kathy Hochul issued an Executive Order declaring a State Disaster Emergency in response to the ongoing monkeypox outbreak. The Executive Order enables the state to respond more swiftly to the outbreak and allows health care professionals to take additional steps that will help get more New Yorkers vaccinated. "After reviewing the latest data on the monkeypox outbreak in New York State, I am declaring a State Disaster Emergency to strengthen our aggressive ongoing efforts to confront this outbreak," Governor Hochul said. "More than one in four monkeypox cases in this country are in New York State, and we need to utilize every tool in our arsenal as we respond. It's especially important to recognize the ways in which this outbreak is currently having a disproportionate impact on certain at-risk groups. That's why my team and I are working around the clock to secure more vaccines, expand testing capacity and responsibly educate the public on how to stay safe during this outbreak." The Executive Order specifically extends the pool of eligible individuals who can administer monkeypox vaccines, including EMS personnel, pharmacists and midwives; allows physicians and certified nurse practitioners to issue non patient specific standing orders for vaccines; and requires providers to send vaccine data to the New York State Department of Health. https://www.governor.ny.gov/news/governor-hochul-declares-state-disaster-emergency-response-ongoing-monkeypox-outbreak

New York State Department of Health (DOH)

For a list of COVID-19 positive cases by county in New York Statehttps://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map? %3Aembed=yes&%3Atoolbar=no&%3Atabs=n

NYS DOH has created a dynamic COVID-19 Tracker which provides COVID-19 information regarding testing, cases, percentages, and fatalities across New York State. It also breaks down cases by county. https://covid19tracker.health.ny.gov/views/NYS-COVID19-Tracker/NYSDOHCOVID-19Tracker-Map? %3Aembed=yes&%3Atoolbar=no&%3Atabs=n For the latest COVID-19 information from NYS DOH https://coronavirus.health.ny.gov/home



New Jersey

Governor Phil Murphy and New Jersey Department of Health Commissioner Judith Persichilli announced two additional vaccination sites for
monkeypox in Camden and Bergen counties. These sites have been added for residents without a confirmed exposure who believe they may have
been exposed or are at high risk for having been exposed to the virus, the New Jersey Department of Health (NJDOH) announced today.
https://www.nj.gov/governor/news/news/562022/approved/20220728b.shtml

Local Updates

New York Blood Center (NYBC)

For the latest updated NYBC information about COVID-19: https://nybc.org/covid-19/

New York City (NYC) Department of Health and Mental Hygiene (DOHMH)

New York City is currently the epicenter of the monkeypox outbreak in the United States. For the latest information including cases, symptoms, testing and vaccine information regarding monkeypox in New York City, please visit https://www1.nyc.gov/site/doh/health/health-topics/monkeypox.page

NYC DOHMH launched a new COVID-19 variants data page. The data on this page show how variants of the virus that causes COVID-19 are spreading in NYC. Variants are versions of the virus with certain sets of mutations. Some variants may result in a COVID-19 infection that is easier to spread, more severe or able to avoid antibodies from vaccines or previous infections. https://www1.nyc.gov/site/doh/covid/covid-19-data-variants.page

For NYC DOHMH updated COVID-19 data page https://www1.nyc.gov/site/doh/covid/covid-19-data.page

As of July 18, 2022, the NYC DOHMH is re-evaluating its COVID-19 Alert level system. For the current COVID-19 Alert level in New York City and guidelines, please visit

https://www1.nyc.gov/site/doh/covid/covid-19-alert-levels.page

Westchester County Department of Health

For the latest breakdown of positive cases in Westchester County as of July 31, 2022 https://wcgis.maps.arcgis.com/apps/dashboards/280339d96db14efd9cc304dba0f3a71d

For the latest COVID-19 information in Westchester including vaccines for children. https://health.westchestergov.com/2019-novel-coronavirus

Putnam County Department of Health

Breakdown of positive cases by towns in Putnam County as of July 29, 2022 https://www.putnamcountyny.com/covid19/

For the latest COVID-19 information https://www.putnamcountyny.com/health/coronavirus/

Dutchess County Department of Health

Breakdown of positive cases in Dutchess County as of July 29, 2022 https://www.dutchessny.gov/Departments/DBCH/covid-19-dashboard.htm

For the latest COVID-19 information:

https://www.dutchessny.gov/Departments/DBCH/2019-Novel-Coronavirus.htm

Orange County Department of Health

Updated COVID-19 dashboard for Orange County, NY as of August 1, 2022 https://ocnygis.maps.arcgis.com/apps/dashboards/21de1fb5ce0c480f95dc0cf2b8b83b71

For the latest COVID-19 information

https://www.orangecountygov.com/1906/2019-Novel-Coronavirus-Information

Rockland County Department of Health

Review Rockland County's dashboard with the latest COVID-19 information regarding cases as of August 1, 2022 https://www.arcgis.com/apps/dashboards/d074e0336e81449393a76d1768ceb096

For the latest COVID-19 information https://rocklandgov.com/departments/health/coronavirus-covid-19/

Healthcare

For the latest COVID-19 information for healthcare facilities from the Greater New York Hospital Association that covers hospitals in the tri-state area. https://www.gnyha.org/



Center for Disaster Medicine Media

Faculty News:

Cómo Prepararse Para Emergencias Con Stop The Bleed

Univision Nueva York

7/30/2022

https://www.univision.com/local/nueva-york-wxtv/contigo/como-prepararse-para-emergencias-con-stop-the-bleed-video

George W. Contreras, M.E.P., M.P.H., M.S., CEM, FACEM, assistant director of the Center for Disaster Medicine and assistant professor in the Institute of Public Health

Every effort is made to provide accurate and complete information in this newsletter. However, New York Medical College cannot guarantee that there will be no errors. NYMC makes no claims, promises or guarantees about the accuracy, completeness, or adequacy of the contents of the newsletters or the articles linked herein

and further expressly disclaims liability for errors and omissions in the contents of this newsletter.

This newsletter is for informational purposes only; it does not constitute medical advice. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.



New York Medical College Center for Disaster Medicine 7 Dana Road Suite 511 Valhalla, New York 10595 914-594-1750

https://www.nymc.edu/center-for-disaster-medicine/

If you wish to unsubscribe from this list, please click here: NYMC ListServ unsubscribe

If you wish to unsubscribe from this list, please click here: <u>NYMC ListServ unsubscribe</u>